CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness

J Immunol. 2000 Aug 1;165(3):1685-91. doi: 10.4049/jimmunol.165.3.1685.

Abstract

It has been suggested that CD4+ T cell proliferative responses to HIV p24 Ag may be important in the control of HIV infection. However, these responses are minimal or absent in many HIV-infected individuals. Furthermore, while in vitro and in vivo responses to non-HIV recall Ags improve upon administration of highly active antiretroviral therapy, there does not appear to be a commensurate enhancement of HIV-specific immune responses. It is possible that CD4+ p24-specific T cells are deleted early in the course of infection. However, it is also possible that a discrete unresponsiveness, or anergy, contributes to the lack of proliferation to p24. To evaluate the possible contribution of unresponsiveness to the lack of CD4+ T cell proliferation to p24 in HIV-infected individuals, we attempted to overcome unresponsiveness. CD40 ligand trimer (CD40LT) and IL-12 significantly increased PBMC and CD4+ T cell proliferative responses to p24 Ag in HIV-infected, but not uninfected, individuals. No increase in proliferative response to CMV Ag was observed. CD40LT exerted its effect through B7-CD28-dependent and IL-12- and IL-15-independent mechanisms. Finally, the increase in proliferation with CD40LT and IL-12 was associated with an augmented production of IFN-gamma in most, but not all, individuals. These data suggest the possible contribution of HIV-specific unresponsiveness to the lack of CD4+ T cell proliferation to p24 Ag in HIV-infected individuals and that clonal deletion alone does not explain this phenomenon. They also indicate the potential for CD40LT and IL-12 as immune-based therapies for HIV infection.

MeSH terms

  • Adjuvants, Immunologic / physiology*
  • Anti-HIV Agents / therapeutic use
  • B7-1 Antigen / physiology
  • CD28 Antigens / physiology
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / metabolism
  • CD4-Positive T-Lymphocytes / virology
  • CD40 Antigens / metabolism*
  • CD40 Ligand
  • Cells, Cultured
  • Clonal Anergy / immunology*
  • Dose-Response Relationship, Immunologic
  • Drug Synergism
  • Epitopes / immunology
  • HIV Core Protein p24 / immunology*
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • HIV Infections / virology
  • Humans
  • Interferon-gamma / biosynthesis*
  • Interleukin-12 / physiology*
  • Interleukin-12 / therapeutic use
  • Interleukin-15 / physiology
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / metabolism
  • Leukocytes, Mononuclear / virology
  • Ligands
  • Lymphocyte Activation / immunology*
  • Membrane Glycoproteins / physiology*
  • Membrane Glycoproteins / therapeutic use

Substances

  • Adjuvants, Immunologic
  • Anti-HIV Agents
  • B7-1 Antigen
  • CD28 Antigens
  • CD40 Antigens
  • Epitopes
  • HIV Core Protein p24
  • Interleukin-15
  • Ligands
  • Membrane Glycoproteins
  • CD40 Ligand
  • Interleukin-12
  • Interferon-gamma